<br>        Inclusion Criteria:<br><br>          -  Written informed consent<br><br>          -  Age: 30 to 80 years<br><br>          -  Adults with AK grade I (mild) or II (moderate)<br><br>        Exclusion Criteria:<br><br>          -  Number of lesions requiring treatment > 10<br><br>          -  Lesion to be treated > 20 mm (maximum diameter)<br><br>          -  Lesions directly adjoining to the eyes, eyelids, nostrils, mouth or mucosal tissue,<br><br>          -  Need for topical treatment of a cancerous area<br><br>          -  Presence of a relapsing, persistent, indurated, thickened, painful, bleeding,<br>             ulcerated and/or rapidly growing lesion<br><br>          -  Presence of a persistent or relapsing lesion despite appropriate treatment with<br>             AKOHDerm or another appropriate treatment<br><br>          -  High risk of progression of AK according as assessed by a medical doctor<br><br>          -  Pharmacological or physical local therapy of AK in the area foreseen for treatment<br>             dur-ing the last 12 weeks<br><br>          -  Treatment with systemic corticosteroids during the last 2 weeks<br><br>          -  Planned concomitant treatment of the same AK lesions during the study in addition to<br>             study treatment<br><br>          -  Other skin diseases in the area of application which might interfere with clinical<br>             signs<br><br>          -  Known predisposition for hypertrophic scarring / keloidosis<br><br>          -  Primary or secondary immunodeficiency<br><br>          -  Treatment with interferons, interferon inducers or immunomodulators during the last 4<br>             weeks<br><br>          -  Pregnancy and lactation<br><br>          -  No reliable contraception in women of child-bearing potential<br><br>          -  Other serious diseases which are according to the investigator in conflict with the<br>             par-ticipation<br><br>          -  Obvious unreliability or lack of cooperation - known addiction to alcohol, medicinal<br>             products or drugs<br><br>          -  Dependent relationship with sponsor or investigator<br><br>          -  Participation in a clinical trial within the last 30 days<br><br>          -  Previous participation in this study<br>